JLK: Operating Loss Continues in Q1 2026, But Global Approvals for Stroke AI Expand
Consolidated Q1 2026 revenue of 4.1 billion KRW (down 15% YoY), operating loss of 3.35 billion KRW, net loss attributable to parent of 3.81 billion KRW (loss widened from 3.21 billion KRW in Q1 2025)
Financial burden increased with 22 billion KRW in borrowings (all due within 1 year) and 11.9 billion KRW in convertible bonds (conversion price 6,709 KRW, exercisable from July 2026)
Equity of 38.4 billion KRW, debt-to-equity ratio of 88.17% (up from 79.95% at year-end 2025)
Cash and short-term financial instruments of 43.8 billion KRW, maintaining short-term liquidity
R&D expenses of 1.06 billion KRW (257% of revenue), accumulated deficit of 87.4 billion KRW
Secured 8 FDA 510(k) approvals and 7 Japanese PMDA approvals for stroke AI solutions, accelerating global market entry
No change in major shareholder, no dividends or share buyback plans (unable to pay dividends due to accumulated losses)